Stable AAV Production

Unique stable helper virus-free AAV production system, addressing the production gap in AAV-based gene therapies.

Stable production of AAV vectors in CAP-GT packaging and producer cells



AAV manufacturing using stable cell lines is the best option for scaling up the production process. Stable AAV producer cell lines avoid the challenges of transient transfections.



Screening of 2 different batches of single cell clones of the stable AAV packaging platform identifies clones with comparable productivity to the transient approach, even before process optimization.



CEVEC is a center of expertise for the production of biopharmaceuticals using a unique human cell-based expression system.

CAP-GT is a fully scalable manufacturing platform for viral vector production. CEVEC has successfully developed CAP-GT suspension cell-derived viral packaging cell lines which enable better scale-up and competitive production costs when compared to adherent cell culture systems. CAP-GT suspension cell lines grow to high cell densities and show excellent productivity for a broad range of viruses. Gene therapy vectors such as lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV) can be produced at industrial scale.

For further information please contact:
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen-Str. 60-62 | 51105 Köln | Germany
Phone +49 (0)221 46020800 | E-Mail info@cevec.com

For business development please contact:
bizdev@cevec.com | www.cevec.com